vs
渤健（BIIB）与Rocket Companies, Inc.（RKT）财务数据对比。点击上方公司名可切换其他公司
Rocket Companies, Inc.的季度营收约是渤健的1.1倍（$2.7B vs $2.5B），渤健净利率更高（12.9% vs 2.5%，领先10.4%），Rocket Companies, Inc.同比增速更快（52.2% vs 2.0%），渤健自由现金流更多（$594.3M vs $-1.3B），过去两年Rocket Companies, Inc.的营收复合增速更高（39.5% vs 0.3%）
渤健是总部位于美国马萨诸塞州剑桥市的跨国生物技术企业，专注于神经系统疾病治疗领域。公司核心产品包括用于多发性硬化症的特菲达、万立能等多款药物，以及治疗脊髓性肌萎缩症的诺西那生钠、治疗弗里德赖希共济失调的Skyclarys，致力于为神经疾病和罕见病患者提供创新疗法。
Rocket Companies, Inc.是美国金融科技及住房服务企业，由丹·吉尔伯特创立，总部位于密歇根州底特律市中心。公司依托旗舰子公司Rocket Mortgage跻身美国最大抵押贷款提供商行列，旗下还拥有Redfin、Forsalebyowner.com、Rocket Money等子品牌。
BIIB vs RKT — 直观对比
营收规模更大
RKT
是对方的1.1倍
$2.5B
营收增速更快
RKT
高出50.2%
2.0%
净利率更高
BIIB
高出10.4%
2.5%
自由现金流更多
BIIB
多$1.9B
$-1.3B
两年增速更快
RKT
近两年复合增速
0.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $2.5B | $2.7B |
| 净利润 | $319.5M | $68.0M |
| 毛利率 | — | — |
| 营业利润率 | — | 6.3% |
| 净利率 | 12.9% | 2.5% |
| 营收同比 | 2.0% | 52.2% |
| 净利润同比 | 32.8% | 100.8% |
| 每股收益（稀释后） | $2.15 | $0.10 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIIBRKT
| Q1 26 | $2.5B | — | ||
| Q4 25 | $2.3B | $2.7B | ||
| Q3 25 | $2.5B | $1.6B | ||
| Q2 25 | $2.6B | $1.4B | ||
| Q1 25 | $2.4B | $1.0B | ||
| Q4 24 | $2.5B | $1.8B | ||
| Q3 24 | $2.5B | $646.9M | ||
| Q2 24 | $2.5B | $1.3B |
净利润BIIBRKT
| Q1 26 | $319.5M | — | ||
| Q4 25 | $-48.9M | $68.0M | ||
| Q3 25 | $466.5M | $-123.9M | ||
| Q2 25 | $634.8M | $-1.8M | ||
| Q1 25 | $240.5M | $-10.4M | ||
| Q4 24 | $266.7M | $33.9M | ||
| Q3 24 | $388.5M | $-22.0M | ||
| Q2 24 | $583.6M | $1.3M |
毛利率BIIBRKT
| Q1 26 | — | — | ||
| Q4 25 | 78.3% | — | ||
| Q3 25 | 73.4% | — | ||
| Q2 25 | 77.1% | — | ||
| Q1 25 | 74.1% | — | ||
| Q4 24 | 76.2% | 58.9% | ||
| Q3 24 | 74.1% | -8.4% | ||
| Q2 24 | 77.8% | 47.4% |
营业利润率BIIBRKT
| Q1 26 | — | — | ||
| Q4 25 | -2.5% | 6.3% | ||
| Q3 25 | 22.0% | -11.5% | ||
| Q2 25 | 28.1% | 1.8% | ||
| Q1 25 | 12.8% | -21.5% | ||
| Q4 24 | 11.9% | 38.1% | ||
| Q3 24 | 18.3% | -76.9% | ||
| Q2 24 | 28.3% | 14.8% |
净利率BIIBRKT
| Q1 26 | 12.9% | — | ||
| Q4 25 | -2.1% | 2.5% | ||
| Q3 25 | 18.4% | -7.7% | ||
| Q2 25 | 24.0% | -0.1% | ||
| Q1 25 | 9.9% | -1.0% | ||
| Q4 24 | 10.9% | 1.9% | ||
| Q3 24 | 15.8% | -3.4% | ||
| Q2 24 | 23.7% | 0.1% |
每股收益（稀释后）BIIBRKT
| Q1 26 | $2.15 | — | ||
| Q4 25 | $-0.35 | $0.10 | ||
| Q3 25 | $3.17 | $-0.06 | ||
| Q2 25 | $4.33 | $-0.01 | ||
| Q1 25 | $1.64 | $-0.08 | ||
| Q4 24 | $1.82 | $0.28 | ||
| Q3 24 | $2.66 | $-0.19 | ||
| Q2 24 | $4.00 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.4B | $2.7B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $18.7B | $22.9B |
| 总资产 | $29.5B | $60.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BIIBRKT
| Q1 26 | $3.4B | — | ||
| Q4 25 | — | $2.7B | ||
| Q3 25 | — | $5.8B | ||
| Q2 25 | — | $5.1B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $1.3B |
总债务BIIBRKT
| Q1 26 | — | — | ||
| Q4 25 | $6.3B | — | ||
| Q3 25 | $6.3B | — | ||
| Q2 25 | $6.3B | — | ||
| Q1 25 | $4.5B | — | ||
| Q4 24 | $6.3B | — | ||
| Q3 24 | $4.5B | — | ||
| Q2 24 | $6.3B | — |
股东权益BIIBRKT
| Q1 26 | $18.7B | — | ||
| Q4 25 | $18.3B | $22.9B | ||
| Q3 25 | $18.2B | $8.9B | ||
| Q2 25 | $17.6B | $7.4B | ||
| Q1 25 | $17.0B | $8.6B | ||
| Q4 24 | $16.7B | $9.0B | ||
| Q3 24 | $16.4B | $8.4B | ||
| Q2 24 | $15.9B | $8.8B |
总资产BIIBRKT
| Q1 26 | $29.5B | — | ||
| Q4 25 | $29.4B | $60.7B | ||
| Q3 25 | $29.2B | $33.6B | ||
| Q2 25 | $28.3B | $30.4B | ||
| Q1 25 | $28.0B | $25.3B | ||
| Q4 24 | $28.0B | $24.5B | ||
| Q3 24 | $28.3B | $25.1B | ||
| Q2 24 | $26.8B | $23.6B |
负债/权益比BIIBRKT
| Q1 26 | — | — | ||
| Q4 25 | 0.34× | — | ||
| Q3 25 | 0.35× | — | ||
| Q2 25 | 0.36× | — | ||
| Q1 25 | 0.27× | — | ||
| Q4 24 | 0.38× | — | ||
| Q3 24 | 0.28× | — | ||
| Q2 24 | 0.40× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-1.2B |
| 自由现金流经营现金流 - 资本支出 | $594.3M | $-1.3B |
| 自由现金流率自由现金流/营收 | 24.0% | -47.2% |
| 资本支出强度资本支出/营收 | — | 1.5% |
| 现金转化率经营现金流/净利润 | — | -18.08× |
| 过去12个月自由现金流最近4个季度 | $2.4B | $-4.0B |
8季度趋势，按日历期对齐
经营现金流BIIBRKT
| Q1 26 | — | — | ||
| Q4 25 | $511.9M | $-1.2B | ||
| Q3 25 | $1.3B | $-50.3M | ||
| Q2 25 | $160.9M | $-1.9B | ||
| Q1 25 | $259.3M | $-797.0M | ||
| Q4 24 | $760.9M | $1.8B | ||
| Q3 24 | $935.6M | $-1.3B | ||
| Q2 24 | $625.8M | $-122.3M |
自由现金流BIIBRKT
| Q1 26 | $594.3M | — | ||
| Q4 25 | $468.0M | $-1.3B | ||
| Q3 25 | $1.2B | $-71.8M | ||
| Q2 25 | $134.3M | $-1.9B | ||
| Q1 25 | $222.2M | $-811.0M | ||
| Q4 24 | $721.6M | $1.8B | ||
| Q3 24 | $900.6M | $-1.4B | ||
| Q2 24 | $592.3M | $-138.3M |
自由现金流率BIIBRKT
| Q1 26 | 24.0% | — | ||
| Q4 25 | 20.5% | -47.2% | ||
| Q3 25 | 48.4% | -4.5% | ||
| Q2 25 | 5.1% | -137.2% | ||
| Q1 25 | 9.1% | -78.2% | ||
| Q4 24 | 29.4% | 103.1% | ||
| Q3 24 | 36.5% | -209.6% | ||
| Q2 24 | 24.0% | -10.6% |
资本支出强度BIIBRKT
| Q1 26 | — | — | ||
| Q4 25 | 1.9% | 1.5% | ||
| Q3 25 | 1.8% | 1.3% | ||
| Q2 25 | 1.0% | 1.1% | ||
| Q1 25 | 1.5% | 1.4% | ||
| Q4 24 | 1.6% | 1.1% | ||
| Q3 24 | 1.4% | 2.9% | ||
| Q2 24 | 1.4% | 1.2% |
现金转化率BIIBRKT
| Q1 26 | — | — | ||
| Q4 25 | — | -18.08× | ||
| Q3 25 | 2.73× | — | ||
| Q2 25 | 0.25× | — | ||
| Q1 25 | 1.08× | — | ||
| Q4 24 | 2.85× | 54.42× | ||
| Q3 24 | 2.41× | — | ||
| Q2 24 | 1.07× | -94.46× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIIB
| Product revenue, net | $1.8B | 71% |
| Royalty revenue on sales of OCREVUS | $317.2M | 13% |
| Contract manufacturing, royalty and other revenue | $246.9M | 10% |
| Biogen's share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO | $94.7M | 4% |
| Alzheimer's collaboration Revenue | $59.5M | 2% |
| Other revenue from anti-CD20 therapeutic programs | $7.2M | 0% |
RKT
| Other | $1.4B | 51% |
| Direct To Customer Segment | $945.8M | 35% |
| Partner Network Segment | $216.7M | 8% |
| Subscription Revenue | $91.3M | 3% |
| Closing Fees | $47.1M | 2% |
| Appraisal Revenue | $10.7M | 0% |
